European Union's human medicines committee (CHMP) said on Friday it is not updating its opinion on Eisai and Biogen's ...

The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's ...

Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American ...

Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi.

Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions.

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has ...

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

The European Commission had requested the committee consider new data on the drug that became available after it had adopted its positive opinion.

Eisai (ESALF) delivered another quarter with Leqembi growth, which is picking up strongly on a sequential basis. Read why I'm ...